Therefore, we conducted this trial to evaluate the safety and efficacy of a sequential treatment defined as three courses of nivolumab (PD-1 inhibitor) first and then combined a PD-1 inhibitor and TILs adoptive T cells with IL-2 in patients with metastatic melanoma. This evidence concerns the gene PDCD1 and metastatic melanoma.